About Tralyte Health

---

Tralyte Health is developing technology to bring calcium testing out of the lab and into the home. We are working on an at-home, calcium monitoring platform intended to provide patients with the potential for faster, more accessible insight into their calcium levels. The initial focus is on hypoparathyroidism, a rare endocrine disorder in which the body has difficulty regulating calcium levels, leading to muscle cramps, fatigue, tingling, and possible cardiac or neurological complications. Some patients require frequent monitoring of their calcium levels but currently rely on centralized lab testing. Our goal is to explore whether clinician-prescribed, home testing could help reduce that dependency and support more timely, informed decision-making, with the potential to expand into more electrolytes over time.

Calcium plays a critical role in nerve function, muscle contraction, and overall metabolic stability. For some patients with inadequately‑controlled hypoparathyroidism, calcium levels can fluctuate quickly and may require closer, clinician monitoring. Today, most patients rely on periodic lab testing, which can delay insight and limit how quickly patients and clinicians can understand changes in calcium levels.

Glucose can be measured using established electrochemical methods that are well-suited for portable, at-home devices.

Calcium behaves differently in the body and cannot be reliably measured using the same approach. Historically, this has limited the ability to develop accurate, user-friendly, calcium monitoring solutions for patient use at home.

Tralyte Health is developing a different sensing approach designed specifically for calcium measurement in “point-of-need” diagnostic settings, meaning settings where testing is intended to be usable anywhere it is needed, including at home.

Tralyte Health’s system uses an optical sensing method to analyze how blood plasma reacts within a controlled environment. This reaction produces a measurable signal that correlates with calcium levels. This approach is being developed to support calcium measurement in a format that can be adapted for at-home use.

Current calcium testing typically requires:

• Travel to a lab or clinic 
• Venous blood draw and processing 
• Delayed results (often days) 

Tralyte Health is developing a solution that aims to:

• Reduce reliance on reference lab visits beyond what is required for the standard of care 
• Support more timely results 
• Improve access to timely, biochemical information

The initial focus is on patients with hypoparathyroidism, a condition that often requires ongoing calcium monitoring. Over time, the underlying technology is being developed to support broader applications in metabolic health, where more frequent, real-time, biochemical insight may help inform disease management.

While hypoparathyroidism is considered a rare disease, the broader implications of calcium monitoring extend beyond a single condition. Calcium is a foundational electrolyte involved in neuromuscular signaling, cardiac rhythm, and overall metabolic stability. Electrolyte imbalance affects millions of people living with chronic disease and post-surgical conditions.

Tralyte Health is beginning with calcium, but the underlying platform is being developed to expand into additional electrolytes over time (e.g. potassium, sodium, lithium, etc.), supporting a more responsive, data-driven approach to informing chronic disease management.

Patients often experience symptoms, but they might not have immediate access to lab testing. This creates a gap between how they feel and what they can measure. For those who are self‑titrating based on symptoms, their symptoms create guesswork on how much or how little to take. Tralyte Health is focused on closing that gap by enabling more timely access to calcium information, potentially helping patients and providers make more informed decisions. 

More accessible calcium monitoring could potentially:

• Help reduce delays between symptoms and treatment
• Support more proactive disease management
• Reduce reliance on episodic lab testing
• Reduce emergency care visits

The broader goal is to shift from reactive care to more continuous, data‑informed insight.

The device is one component of a larger platform. Effective at-home diagnostics require:

• Reliable measurement technology 
• A way to manage and interpret data 
• Integration into clinical workflows 

Tralyte Health is developing a broader point-of-need solution that brings these elements together.

The calcium monitoring platform will include a calcium monitoring device and a companion app for smartphones. The device is fully functional on its own, capturing calcium levels. The app is optional, serving to track calcium levels over time.

Tralyte Health is starting with calcium monitoring but sees potential to expand into additional electrolytes relevant to metabolic health such as potassium, sodium, lithium, etc. The long‑term goal is to enable more comprehensive, timely insight into the body’s chemistry, supporting a more informed approach to managing a range of conditions. 

Healthcare is increasingly moving toward decentralized, patient‑centered models, where diagnostics and monitoring happen outside of traditional clinical settings. At‑home testing, when validated and accessible, can play a key role in improving the patient experience and supporting more informed clinical decision-making. 

Tralyte Health is currently in the development stage, focused on building its alpha prototype, advancing its patent-pending, sensing technology, generating supporting data, and preparing for future regulatory submissions. The company is raising its pre‑seed round of funding and does not yet offer a commercial product. It continues building the evidence needed to support future availability. 

Tralyte Health’s technology is in active development and will require additional testing and regulatory review before it can be made available. The company is focused on advancing the science and building the foundation needed to support future patient access. We anticipate a commercial entry in the second half of 2028, pending successful development and clearance. 

No. Tralyte Health’s technology is being developed as a complement to standard clinical care, not a replacement. Patients will continue to work with their clinicians to determine when and how testing should be used, in alignment with the standards of care as determined by a healthcare professional.

Tralyte Health’s technology is being developed for clinician‑directed use. Specific requirements, including whether a prescription is needed, will depend on future regulatory review. 

Tralyte Health is designing its system with privacy and security in mind. As development continues, the company will follow applicable regulations and industry best practices to help protect patient information.